Loading...
XNAS
LXRX
Market cap508mUSD
Dec 05, Last price  
1.40USD
1D
-1.41%
1Q
28.44%
Jan 2017
-89.88%
IPO
-98.83%
Name

Lexicon Pharmaceuticals Inc

Chart & Performance

D1W1MN
XNAS:LXRX chart
P/E
—
P/S
16.37
EPS
—
Div Yield, %
—
Shrs. gr., 5y
22.35%
Rev. gr., 5y
-37.35%
Revenues
31m
+2,481.48%
75,680,00072,798,00050,118,00032,321,00010,700,0004,908,0001,849,0001,089,0002,222,00022,854,000130,014,00083,337,00090,335,00063,209,000322,073,00023,995,000298,000139,0001,204,00031,081,000
Net income
-200m
L+13.15%
-36,315,000-54,311,000-58,794,000-76,860,000-82,780,000-101,775,000-116,215,000-110,211,000-104,126,000-100,294,000-4,682,000-141,429,000-129,050,000-120,548,000130,133,000-70,184,000-88,268,000-103,128,000-177,119,000-200,403,000
CFO
-179m
L+10.43%
23,442,000-56,909,000-74,323,000-95,600,000-89,016,000-82,368,000-87,938,000-94,460,000-91,079,000-75,622,000184,776,000-175,628,000-185,394,000-148,607,000113,807,000-142,969,000-87,017,000-88,851,000-161,897,000-178,780,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.
URL
https://www.lexpharma.com/
IPO date
Apr 07, 2000
Employees
135
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT